PROPANC BIOPHARMA INC (PPCB) Stock Income Statement
NASDAQ:PPCB - Nasdaq - US74346N7012 - Common Stock - Currency: USD
| TTM (2024-12-31) | 2024 (2024-6-30) | 2023 (2023-6-30) | 2022 (2022-6-30) | 2021 (2021-6-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 1.19M | 1.54M | 1.78M | 1.99M | 1.81M | |||
| Research and Development | 233.90K | 248.10K | 247.90K | 256.10K | 231.00K | |||
| Selling, General, and Administrative Expenses | 951.00K | 1.29M | 1.53M | 1.73M | 1.58M | |||
| Operating Income | -1.19M | -1.54M | -1.78M | -1.99M | -1.81M | |||
| Interest Income/Expense | -475.70K | -468.20K | -1.06M | -704.70K | -427.20K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | 0.00 | |||
| Non Recurring Items | -9.60K | 54.60K | 43.50K | -17.50K | 99.90K | |||
| Income Before Taxes | -1.67M | -1.95M | -2.79M | -2.71M | -2.14M | |||
| Income Tax | -500.00 | -129.10K | -129.80K | -55.00K | -113.40K | |||
| Net Income | -1.69M | -2.01M | -3.13M | -2.66M | -2.03M | |||
| EBITDA | N/A | -1.54M | -1.77M | -1.99M | -1.81M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -703.62 | -1.42K | -104.23K | -1.95M | -668.63 | |||
| Statistics | ||||||||
All data in USD